Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)
A. O'Donnell (Washington, DC, United States of America), I. Gonda (Hayward, CA, United States of America), D. Cipolla (Hayward, CA, United States of America), J. Froehlich (Hayward, CA, United States of America), A. Davis (Research Triangle Park, NC, United States of America), C. Haworth (Cambridge, United Kingdom)
Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM)
Disease area: Airway diseases, Respiratory infections
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Related content which might interest you: